Subscribe To

Price Alert Latest News Economic Calendar News

ACHV / Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 750 adult smokers. Read More

Demo Live Account See Partner Details

Content Topics

Achieve

Life

Sciences

Initiates

Pivotal

Trial

Cytisinicline

Smoking

Cessation

Stock

ACHV

Posted: Jan 25 2022, 11:08

Author Name: Benzinga

ACHV News

By Seeking Alpha
May 28, 2023

Achieve: Exciting Smoking Cessation Drug Approval Could Come Soon

Efficacy: Phase 3 ORCA-3 trial showed significant efficacy of cytisinicline in smoking cessation, reinforcing data from ORCA-2. Safety: Cytisinicline

By Market Watch
May 23, 2023

Achieve Life Sciences says confirmatory late-stage trial of its treatment for quitting smoking achieved positive results

Achieve Life Sciences Inc. ACHV, +12.88% said Tuesday a second confirmatory late-stage trial of its cytisinicline for quitting smoking and nicotine de

By GlobeNewsWire
April 26, 2023

Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023

SEATTLE and VANCOUVER, British Columbia, April 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmace

By Seeking Alpha
March 16, 2023

Achieve Life Sciences, Inc. (ACHV) Q4 2022 Earnings Call Transcript

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Nicole Jones - Investor Rel

By Seeking Alpha
January 28, 2023

Achieve Life Sciences: All Eyes On Phase 3 Data For Smoking Cessation Drug

ORCA-2 phase 3 trial was a success where Cytisinicline has shown statistically significant improvement in quit rates and robust safety profile. Phase

By Seeking Alpha
November 14, 2022

Achieve Life Sciences, Inc. (ACHV) Q3 2022 Earnings Call Transcript

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Nicole Jones - Investor

By Seeking Alpha
May 12, 2022

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q1 2022 Results - Earnings Call Transcript

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Bencich - CEO & Director

By Seeking Alpha
April 4, 2022

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.